ROS1 and non-small cell lung carcinoma: In particular, in patients with advanced NSCLC that harbored CD74-, SLC34A2-, SDC4-, or EZR-ROS1 fusions, those with isolated central nervous system progression and positive ctDNA faced higher risk of extra-CNS progression (32% vs. 7%) [104].